Loading
Latest filing published 01 Sept 2026 for Quoin Pharmaceuticals, Ltd., €86k.
Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Michael Myers discloses dealings in Quoin Pharmaceuticals, Ltd. to SEC (Form 4). In total, 6 filings cover trades dated from 3 September 2024 to 31 August 2026.
On the market, this insider has only ever bought: 6 purchases, €352k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2026 alone, the filings show 1 purchase and no sales.
A typical purchase (the median) is worth €11k. Clusters matter here: 6 out of 6 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. Looking at 5 purchases old enough to measure, the stock rose over the following 90 days in 0% of cases; the median change was -2.6%. This is a record of the past, not a forecast.
The latest filing, published on 1 September 2026, reports an open-market purchase of €86k in Quoin Pharmaceuticals, Ltd. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations